Finance, Grants, Deals

Shire mulls revised Takeda proposal

Shire Plc has secured additional time from the UK competition authority to review a proposed bid from Takeda Pharmaceutical Company Ltd that values the Dublin-based company at £46 billion. The parties have until 8 May to reach a decision.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Ireland

Shire sells oncology assets

Shire Plc announced on 16 April that it has reached a deal to sell its oncology business to Servier SAS of France for $2.4 billion. The transaction was described by the company as a move to sharpen its focus on its portfolio for drugs treating rare diseases.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Ireland

Promethera acquires Baliopharm

The Belgium-based cell therapy company Promethera Biosciences SA has branched out into biologics with the acquisition of Baliopharm AG, a Swiss developer of therapies for immune-mediated inflammatory diseases and cancer. Financial details of the transaction were not disclosed.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium

Funding for lung treatment

Enterprise Therapeutics Ltd, which is developing compounds for respiratory diseases by targeting unwanted mucus in the lungs, has raised £29 million in an oversubscribed Series B financing round co-led by Versant Ventures and the Novartis Venture Fund.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

GSK gene therapy deal

Orchard Therapeutics Ltd has come closer to its goal of becoming a global supplier of gene therapies following an agreement with GlaxoSmithKline Plc to take over that company’s portfolio of gene therapies for rare diseases.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Wilson bought by Alexion

Wilson Therapeutics AB is to be bought by Alexion Pharmaceuticals Inc for $855 million in a deal that underscores the potential of the Swedish company’s lead product for Wilson disease, a rare genetic disorder that prevents the body from regulating copper. The disease can lead to liver and brain damage.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Sweden

MorphoSys launches US IPO

MorphoSys AG has filed a registration statement with the US Securities and Exchange Commission to make an initial public offering of its shares on the Nasdaq market. The offering will consist of up to 8.3 million American Depositary Shares (ADSs), the German company said on 9 April.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany

Novartis to acquire AveXis

Novartis appears set to become a first mover in gene therapy again with the agreed acquisition of AveXis Inc, a company with a late-stage gene replacement therapy for treating spinal muscular atrophy (SMA).

Location

Switzerland

Venture group becomes independent

Edmond de Rothschild Investment Partners (EdRIP) has separated from the Rothschild banking group to become an independent firm owned by its 55 employees and trading under the new name Andera Partners. The move comes as European venture capital becomes more international, and competition for promising assets increases.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France

Cellectis’ allogeneic portfolio gets boost

France-based Cellectis SA has acquired a new partner for its portfolio of products for cancer that are based on donor T cells that have been engineered to target specific antigen on cancer cells. The allogeneic portfolio had been licensed to Pfizer Inc and Servier.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France

Syndicate content